Urinary DNA Test Boosts Bladder Cancer Detection
- A novel urinary DNA methylation test demonstrates superior sensitivity in detecting high-grade or invasive bladder cancer, outperforming the NMP22 test adn urine cytology.
- A prospective study involving 1099 patients presenting with hematuria across 10 different sites revealed that 219 (19.9%) were diagnosed with bladder cancer.
- The study focused on evaluating the effectiveness of a urinary DNA (PENK) methylation test.
Urinary DNA Methylation Test Enhances Bladder Cancer detection
Table of Contents
- Urinary DNA Methylation Test Enhances Bladder Cancer detection
- Urinary DNA Methylation Test: Your Questions Answered
- What is the Urinary DNA Methylation Test?
- how accurate is the Urinary DNA Methylation Test for bladder cancer?
- How does the urinary DNA Methylation Test compare to other bladder cancer tests like NMP22 and urine cytology?
- What do positive and negative predictive values mean for this test?
- can the Urinary DNA Methylation Test be combined with other tests for better accuracy?
- Is the Urinary DNA Methylation Test effective for all patients, nonetheless of age or smoking status?
- What are the benefits and drawbacks of combining the Urinary DNA Methylation Test with NMP22 or urine cytology?
- What is the role of DNA methylation in bladder cancer?
- Where was the study on the Urinary DNA Methylation Test published?
A novel urinary DNA methylation test demonstrates superior sensitivity in detecting high-grade or invasive bladder cancer, outperforming the NMP22 test adn urine cytology.
Improved Detection of High-Grade Bladder Cancer
A prospective study involving 1099 patients presenting with hematuria across 10 different sites revealed that 219 (19.9%) were diagnosed with bladder cancer. Among thes cases, 176 were classified as high-grade or invasive.
The study focused on evaluating the effectiveness of a urinary DNA (PENK) methylation test. The results, published in JAMA oncology by Gab Jeong, MD, PhD, and colleagues from Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, indicated significant potential for early and accurate detection.
The urinary DNA methylation test identified high-grade or invasive bladder cancer in 157 out of 176 patients, achieving a sensitivity of 89.2%. It also detected overall bladder cancer in 171 out of 219 patients, with a sensitivity of 78.1%. However, the test’s specificity for ruling out high-grade or invasive disease (87.8%) and overall bladder cancer (88.8%) was lower compared to the NMP22 test (91.6% and 91.9%, respectively) and urine cytology test (99.5% for both).
The positive predictive value of the urinary DNA test for high-grade or invasive bladder cancer was 61.3%, while its negative predictive value was notably high at 97.6%.
Combining Tests for Enhanced Accuracy
Researchers explored the impact of combining the urinary DNA methylation test with other diagnostic methods. Adding urine cytology to the urinary DNA methylation test increased sensitivity to 90.2% while maintaining a specificity of 87.6% for high-grade or invasive bladder cancer.
Moreover, when all three tests were combined, the sensitivity for detecting high-grade or invasive disease reached 92.4%, with a specificity of 81.5%.
Consistent Performance across Demographics
According to Dr. Jeong’s team,
In our study, the urinary DNA methylation test maintained higher sensitivity compared with NMP22 or urine cytology tests, irrespective of age or smoking status.
They added,
These results suggest that the robust performance of the urinary DNA methylation test is consistent irrespective of factors that may affect the DNA methylation status. Combining the NMP22 or urine cytology test with the urinary DNA methylation test increased sensitivity by approximately 3% while decreasing specificity by around 6%.
The team suggests that while there may be clinical benefits to combining these tests, the current costs remain a significant barrier.
study Details
The research was supported by Genomictree Inc. For a comprehensive list of disclosures,please refer to the original publication in JAMA Oncology.
Urinary DNA Methylation Test: Your Questions Answered
This article provides answers to frequently asked questions about the urinary DNA methylation test and its role in bladder cancer detection. It is based on a recent study published in JAMA Oncology that investigated the effectiveness of this novel test.
What is the Urinary DNA Methylation Test?
The urinary DNA methylation test is a non-invasive diagnostic tool designed to detect bladder cancer by analyzing specific DNA markers in a urine sample.Specifically, it focuses on the methylation patterns of the PENK gene. DNA methylation is a process that can alter gene expression, and abnormal methylation patterns are often associated with cancer. The test identifies these abnormal methylation patterns, indicating the potential presence of bladder cancer.
how accurate is the Urinary DNA Methylation Test for bladder cancer?
The JAMA Oncology study involving 1099 patients presenting with hematuria revealed the following accuracy rates for the urinary DNA methylation test:
Sensitivity for High-Grade or Invasive Bladder Cancer: 89.2%
Sensitivity for Overall Bladder Cancer: 78.1%
Specificity for High-Grade or Invasive Bladder Cancer: 87.8%
Specificity for overall Bladder Cancer: 88.8%
Sensitivity refers to the test’s ability to correctly identify individuals who have bladder cancer, while specificity refers to the test’s ability to correctly identify individuals who do not have bladder cancer.
How does the urinary DNA Methylation Test compare to other bladder cancer tests like NMP22 and urine cytology?
The urinary DNA methylation test demonstrates superior sensitivity compared to the NMP22 test and urine cytology, especially for high-grade or invasive bladder cancer. However, its specificity is slightly lower than these customary methods.
Here’s a comparison of the tests:
| Test | Sensitivity (High-Grade/Invasive) | Specificity (High-Grade/Invasive) |
| ——————————– | ———————————— | ———————————– |
| Urinary DNA Methylation Test | 89.2% | 87.8% |
| NMP22 Test | N/A | 91.6% (overall) |
| Urine Cytology | N/A | 99.5% (overall) |
Note: The NMP22 test and urine cytology don’t have sensitivity numbers available in the source article.
What do positive and negative predictive values mean for this test?
The positive predictive value (PPV) of the urinary DNA methylation test for high-grade or invasive bladder cancer is 61.3%. This means that if the test is positive, there is a 61.3% chance that the individual truly has high-grade or invasive bladder cancer.
The negative predictive value (NPV) is notably high at 97.6%. This indicates that if the test is negative, there is a 97.6% chance that the individual does not have high-grade or invasive bladder cancer.
can the Urinary DNA Methylation Test be combined with other tests for better accuracy?
yes, combining the urinary DNA methylation test with urine cytology can enhance accuracy. The study showed that:
Adding urine cytology to the urinary DNA methylation test increased sensitivity to 90.2% while maintaining a specificity of 87.6% for high-grade or invasive bladder cancer.
When all three tests (urinary DNA methylation, urine cytology, and NMP22) were combined, the sensitivity for detecting high-grade or invasive disease reached 92.4%,with a specificity of 81.5%.
Is the Urinary DNA Methylation Test effective for all patients, nonetheless of age or smoking status?
According to Dr. Jeong’s team, the urinary DNA methylation test maintained higher sensitivity compared with NMP22 or urine cytology tests, irrespective of age or smoking status. This suggests that the test’s performance is consistent across different demographics and risk factors.
What are the benefits and drawbacks of combining the Urinary DNA Methylation Test with NMP22 or urine cytology?
Benefits:
Increased sensitivity in detecting high-grade or invasive bladder cancer (approximately 3% increase).
Drawbacks:
Decreased specificity (around 6% decrease).
Increased costs, which might potentially be a notable barrier.
What is the role of DNA methylation in bladder cancer?
DNA methylation is a key epigenetic mechanism involved in regulating gene expression. In the context of bladder cancer, abnormal DNA methylation patterns can lead to the silencing of tumor suppressor genes or the activation of oncogenes, contributing to the development and progression of the disease. The urinary DNA methylation test exploits these cancer-specific methylation alterations to detect the presence of bladder cancer cells in urine samples.
Where was the study on the Urinary DNA Methylation Test published?
The results of the study were published in JAMA oncology*. The lead author is Gab Jeong, MD, PhD, from Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea. The research was supported by Genomictree Inc.